Invokana Tablet, Film Coated
Product Images NDC 50090-5029

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Invokana (NDC 50090-5029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Invokana 01)

Chemical structure diagram of canagliflozin, the active ingredient in INVOKANA 300 mg film-coated oral tablets, showing its molecular composition with water of crystallization noted as 1/2 H2O.*

FDA Label Image

Figure 1 (Invokana 02)

A line chart showing the least squares mean change in HbA1c (%) from baseline over 52 weeks for three treatments: canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride. The x-axis represents study weeks from 0 to 52, and the y-axis represents change in HbA1c from 0 to about -1.2. Data points with error bars illustrate changes over time, highlighting trends during the study period.*

FDA Label Image

Figure 2 (Invokana 03)

A line graph showing the least squares mean change in HbA1c (%) from baseline over a 52-week study period. Two treatment groups are compared: Canagliflozin 300 mg and Sitagliptin 100 mg. The x-axis indicates study weeks, and the y-axis represents HbA1c change. The graph includes error bars reflecting standard error.*

FDA Label Image

Figure 3 (Invokana 04)

A line graph comparing the percentage of subjects with events over time (weeks) between a placebo group and a canagliflozin (Cana) group, with the Cana group showing a slightly lower event percentage. The graph includes a hazard ratio with confidence interval and a table below indicating the number of subjects remaining in each group at various time points.*

FDA Label Image

Figure 4 (Invokana 05)

A Kaplan-Meier survival curve graph comparing the percentage of subjects with events over time (weeks) between canagliflozin (Cana) and placebo groups. The solid line represents placebo, and the dashed line represents Cana. The graph includes hazard ratio (HR 0.70, 95% CI 0.59-0.82) and a table below showing the number of subjects at risk in each group at multiple time points up to 182 weeks.*

FDA Label Image

Label Image (Lbl500905029)

INVOKANA 300 mg film-coated oral tablets by A-S Medication Solutions. The label specifies canagliflozin as the active ingredient with 90 tablets per package. Storage directions indicate to keep between 68 and 77 degrees Fahrenheit. The label includes the NDC 50090-5029 and a QR code for dosage package insert information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.